奥沙利铂联合替吉奥胶囊治疗晚期胃癌的观察

Observation of Oxaliplatin combined with S-1 capsules in treatment of advanced gastric cancer

目的探讨奥沙利铂联合替吉奥胶囊治疗晚期胃癌临床的疗效与安全性。方法对2010年6月—2012年6月郑州人民医院收治的60例晚期胃癌患者进行观察分析,随机分成两组,观察组30例采用奥沙利铂联合替吉奥胶囊治疗,对照组30例采用顺铂加5氟尿嘧啶加甲酰四氢叶酸治疗。同时进行实验方法研究,探讨奥沙利铂联合替吉奥胶囊抑制胃癌SGC-7901细胞的增殖及诱导细胞凋亡的作用。结果观察组总有效率为73.3%,对照组总有效率为50.0%,观察组明显高于对照组,有明显的统计学差异性(P<0.05)。毒副作用最常见的不良反应是胃肠道反应和造血、骨髓抑制等。体外实验中,奥沙利铂与替吉奥联合组24h细胞增殖抑制率高于单药组抑制率,差别有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥胶囊是有效、安全的化疗方案,值得推广。

Objective To investigate the clinical efficacy and safety of Oxaliplatin combined with S - 1 capsules for the treatment of advanced gastric cancer. Methods Totally 60 admitted patients with advanced gastric cancer from June 2010 to June 2012 in Zhengzhou People~ Hospital were randomly divided into two groups. One group,defined as observa- tion group,was treated with Oxaliplatin combined with S - 1 capsules,and the other group,named control group, used the Cisplatin,5 -fluorouraeil combined with Leucovorin therapy. At the same time,discuss the roles of Oxaliplatin combined with S - 1 capsules on reducing gastric SGC - 7901 cells proliferation and inducing apoptosis. Results The total effec- tive rate was 73.3% in the observation group, which is significantly higher than that 50. 0% in the control group. There is a statistically significant difference （ P 〈 0. 05 ）. The most common side effects are gastrointestinal adverse reactions and blood,bone marrow suppression. In vitro experiment, Oxaliplatin combined with S - 1 capsules group of 24 h cell prolifer- ation inhibition rate was higher than that of single drug groups, the difference was statistically significant. Conclusion Oxaliplatin combined S - 1 capsules are efl＇ective and safe chemotherapy,worthy of promotion.